GlassScriptPhysician profile
Collin Mayemura
NPI 1609452366
$2,324.62
in general payments reported to CMS, 2019-2025
12 companies · $1,453 in 2025
The $1,453 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $872 · 2025: $1,453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,324.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $612.63 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $413.13 | 2024-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $342.20 | 2024-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $271.08 | 2024-2025 | Xifaxan |
| Madrigal Pharmaceuticals | $261.65 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $205.55 | 2024-2025 | |
| Celltrion USA INC. | $70.43 | 2025 | Vegzelma |
| Boston Scientific Corporation | $45.35 | 2024 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Phathom Pharmaceuticals, INC. | $34.16 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $31.94 | 2024 | Dificid, Zinplava, Prevymis |
| Ferring Pharmaceuticals INC. | $18.55 | 2024 | Rebyota |
| Ardelyx, INC. | $17.95 | 2024 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Collin Mayemura listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.